DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU-Reference-Cited by-同舟云学术

DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU

Published:2007-06 Issue:2 Volume:24 Page:251-258
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Zhang Hong,Li You-Ming,Zhang Hao,Jin Xi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF02698048.pdf

Reference24 articles.

1. Ciccolini J, et al. Toxic death-case after capecitabine+ oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency.Cancer Chemother Pharmacol 2006;58: 272–275.

2. Lazar A, et al. Multiple organ fail due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.Onkologie 2004;27: 559–562.

3. van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.Ann Clin Biochem 2003;40: 41–45.

4. Ciccolini J, et al. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPYD) activity.J Clin Pharm Ther 200429: 307–315.

5. Ritschel, W.A.Handbook of Basic Pharmacokinetics, 2nd ed. Drug Intelligence Publications, 1980, pp 413–426. http://www.boomer.org/c/p3/c02/c0204.html

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy;British Journal of Clinical Pharmacology;2024-07-30

2. The influence of polymorphism of genes associated with breast cancer on the effectiveness of drug antitumor therapy;Tumors of female reproductive system;2024-07-26

3. Commentary: The pharmacogenomic landscape of an Indigenous Australian population;Frontiers in Pharmacology;2024-05-15

4. Genetic Variants as Predictors of the Success of Colorectal Cancer Treatments;Cancers;2023-09-22

5. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?;British Journal of Clinical Pharmacology;2023-03-30